A new trading day began on Friday, with Abbvie Inc (NYSE: ABBV) stock price down -1.11% from the previous day of trading, before settling in for the closing price of $216.75. ABBV’s price has ranged from $164.39 to $244.81 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -14.67% over the past five years. Meanwhile, its annual earnings per share averaged 3.17%. With a float of $1.77 billion, this company’s outstanding shares have now reached $1.77 billion.
Abbvie Inc (ABBV) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – General Industry. The insider ownership of Abbvie Inc is 0.09%, while institutional ownership is 74.58%. The most recent insider transaction that took place on Aug 22 ’25, was worth 13,231,264. Before that another transaction happened on Aug 21 ’25, when Company’s Former Director proposed sale 90,000 for $211.04, making the entire transaction worth $18,993,948.
Abbvie Inc (ABBV) Performance Highlights and Predictions
In its latest quarterly report, released on 12/31/2024, the company reported earnings of 2.16 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.33% during the next five years compared to -14.67% drop over the previous five years of trading.
Abbvie Inc (NYSE: ABBV) Trading Performance Indicators
Here are Abbvie Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.35. Likewise, its price to free cash flow for the trailing twelve months is 19.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.33, a number that is poised to hit 3.15 in the next quarter and is forecasted to reach 14.27 in one year’s time.
